Company Overview and News
Cynata Therapeutics Ltd (ASX:CYP) has been granted a patent for its proprietary Cymerus™ mesenchymal stem cell technology in the U.S.
Cynata Therapeutics Ltd (ASX:CYP) has crossed a major milestone by successfully completed the pre-IND (investigational new drug) meeting with the U.S. FDA (Food and Drug Administration).
Glioblastoma Multiforme Pipeline Therapeutics Development 2017 report provides Companies Involved in Therapeutics Development like AbbVie, Novartis AG, Novogen, Merck KGaA and others. Report encapsulates all the dormant and discontinued Glioblastoma Multiforme pipeline projects.
Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology.
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.
Cynata Therapeutics (ASX:CYP) has some very interesting news on the horizon, with the company entering an ASX trading halt pending an update on its Phase 1 clinical trial. The halt will remain in place until the opening of trade on Wednesday 17th May 2017, or earlier if an announcement will be made to the market.
Research and Markets has announced the addition of the "Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report to their offering.
Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.
Cobalt Blue Holdings (ASX:COB) was only recently minted on the ASX, yet the company has already outlined a rapid growth story.
White Cliff Minerals (ASX:WCN) has near-term gold production potential, and is currently working towards a new JORC Resource for the high-grade Aucu gold project located in the Kyrgyz Republic of central Asia.
Bluechiip (ASX:BCT) has developed an IT based temperature and identification tracking solution for biosamples in the health and life sciences industry.
These events are tailor-made for private and professional investors who have exposure to equities, particularly growth stocks - or indeed anyone who is considering putting their money to work in dynamic sectors such as mining, oil and gas, technology and drug discovery.
Cynata Therapeutics (ASX:CYP) is a stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™.
Legend Mining (ASX:LEG) is exploring on one of Australia's host post codes, the Fraser Range of Western Australia, with partner Creasy Group.
Furthermore, Cynata expects to receive $4 million towards the end of this month via the issue of shares to FUJIFILM, as part of a strategic partnership.
The halt will remain in place until the opening of trade on Monday 23rd January 2017, or earlier if an announcement is made to the market.
GvHD is a medical complication following the receipt of transplanted tissue from a genetically different person. Cynata has selected five leading NHS hospitals in England to participate in this clinical trial, which involves its lead Cymerus™ mesenchymal stem cell (MSC) product, CYP-001. The company had already received authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC).
ReportsnReports.com adds "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
ReportsnReports.com adds "Postherpetic Neuralgia - Pipeline Review, H2 2016" to its store providing an overview of the Postherpetic Neuralgia's therapeutic pipeline with comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
RnRMarketResearch.com adds "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016" market research report that provides an overview of its therapeutic pipeline with comprehensive information and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
-- UK regulatory authority MHRA approves Phase 1 trial with Cymerus(TM) MSCs -- World first clinical trial with allogeneic iPSC-derived product -- Major milestone for stem cell therapeutics and regenerative medicine -- Cements Cynata's global leadership in second generation MSC therapeutics
Cynata Therapeutics Ltd (ASX:CYP) has been granted a trading halt by the ASX, with its shares placed in pre-open. Cynata requested the halt pending details regarding the company’s clinical trial authorisation application for its lead Cymerus mesenchymal stem product with the UK Medicines and Health Care Product Regulatory Agency (MHRA). The halt will remain in place until the opening of trade on Wednesday 21st September 2016, or earlier if an announcement is made to the market.
Cynata Therapeutics (ASX:CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™.
RnRMarketResearch.com adds "Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape" 2016 market research report to its store providing an in-depth assessment of the current trends in the global stem cell therapy sector with a particular focus on the technological, competitive and R&D landscape. Along with extensive secondary research efforts, a targeted industry survey of experts and key opinion leaders in the stem cell therapies field was taken to gather opinions on the global trends and future commercial prospects of the stem cell therapies market.
It's fast, free and easy to sign in with Facebook, Google, or Yahoo. Be connected on your terms - we won't share anything without your permission
1h - Asif
16h - Asif